Last reviewed · How we verify
Androgen receptor targeted therapy
This therapy targets the androgen receptor to modulate hormone-dependent signaling pathways, typically used in hormone-sensitive cancers.
This therapy targets the androgen receptor to modulate hormone-dependent signaling pathways, typically used in hormone-sensitive cancers. Used for Prostate cancer (likely indication given AR targeting and phase 3 status).
At a glance
| Generic name | Androgen receptor targeted therapy |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Androgen receptor antagonist or modulator |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Androgen receptor targeted therapies work by blocking or modulating the androgen receptor, a nuclear hormone receptor that drives proliferation in androgen-dependent cancers. By inhibiting this pathway, the drug suppresses tumor growth in conditions where androgen signaling is a primary driver. This approach is commonly used in prostate cancer and other androgen-responsive malignancies.
Approved indications
- Prostate cancer (likely indication given AR targeting and phase 3 status)
Common side effects
- Hot flashes
- Fatigue
- Sexual dysfunction
- Gynecomastia
Key clinical trials
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PHASE3)
- A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (PHASE2)
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (PHASE1, PHASE2)
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (PHASE2)
- A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants (PHASE1)
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (PHASE3)
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: